Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierChimie et Biologie des Membranes et des Nanoobjets [CBMN]
dc.contributor.authorABARKAN, Myriam
hal.structure.identifierInstitut des Maladies Neurodégénératives [Bordeaux] [IMN]
dc.contributor.authorFOIS, Giulia
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorVOUILLAC-MENDOZA, Caroline
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorAHMED, Serge
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorGUILLEM, Karine
dc.date.accessioned2024-05-02T06:53:35Z
dc.date.available2024-05-02T06:53:35Z
dc.date.issued2023
dc.identifier.issn0893-133Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/199558
dc.description.abstractEnNicotine addiction develops after prolonged drug use and escalation of drug intake. However, because of difficulties in demonstrating escalation of nicotine use in rats, its underlying neuroadaptations still remain poorly understood. Here we report that access to unusually high doses of nicotine (i.e., from 30 µg to 240 µg/kg/injection) for self-administration precipitated a rapid and robust escalation of nicotine intake and increased the motivation for the drug in rats. This nicotine intake escalation also induced long-lasting changes in vmPFC neuronal activity both before and during nicotine self-administration. Specifically, after escalation of nicotine intake, basal vmPFC neuronal activity increased above pre-escalation and control activity levels, while ongoing nicotine self-administration restored these neuronal changes. Finally, simulation of the restoring effects of nicotine with in vivo optogenetic inhibition of vmPFC neurons caused a selective de-escalation of nicotine self-administration.
dc.language.isoENen_US
dc.title.enAltered neuronal activity in the ventromedial prefrontal cortex drives nicotine intake escalation
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s41386-022-01428-9en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Pharmacologieen_US
bordeaux.journalNeuropsychopharmacologyen_US
bordeaux.page887-896en_US
bordeaux.volume48en_US
bordeaux.hal.laboratoriesCBMN : Chimie & de Biologie des Membranes & des Nano-objets - UMR 5248en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionBordeaux INPen_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04237136
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neuropsychopharmacology&rft.date=2023&rft.volume=48&rft.issue=6&rft.spage=887-896&rft.epage=887-896&rft.eissn=0893-133X&rft.issn=0893-133X&rft.au=ABARKAN,%20Myriam&FOIS,%20Giulia&VOUILLAC-MENDOZA,%20Caroline&AHMED,%20Serge&GUILLEM,%20Karine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée